UCB Pharma
LeaveRussia detail: Scaling Back
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease.
Decision trail
UCB is still bringing medicines to patients in Russia but we have reviewed the way in which we conduct our business there. Profits generated in Russia will be donated to NGOs to help the people of Ukraine. We have already stopped enrolling new patients and are not starting up any new sites or clinical trials in Russia. We are no longer undertaking marketing activities and are exploring other steps we can take to support the sanctions. Revenue decreased in 2024 vs 2023 by more than -10%.
Local stats (LeaveRussia)
Status history since 2022
- 03/08/2026 — scaling back · Imported from KSE LeaveRussia
Exposure profile
Full exposure profile is a Professional feature
Energy, transport and commodity exposure, supplier/customer links in the region and sanctioned-party proximity.
Upgrade to Professional